MARKET

SCNX

SCNX

Scienture Holdings, Inc
NASDAQ
3.760
+0.050
+1.35%
After Hours: 3.600 -0.16 -4.26% 19:43 10/06 EDT
OPEN
3.230
PREV CLOSE
3.710
HIGH
4.140
LOW
3.230
VOLUME
218.02K
TURNOVER
--
52 WEEK HIGH
65.00
52 WEEK LOW
3.230
MARKET CAP
6.18M
P/E (TTM)
-0.0809
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at SCNX last week (0928-1002)?
Weekly Report · 1d ago
Upcoming Stock Splits This Week (October 5–9) – Stay Invested
TipRanks · 2d ago
Analyst Maintains Buy Rating on Scienture, Keeps 12-Month Price Target Unchanged at $1.50 on Strength of Arbli Commercial Progress
TipRanks · 3d ago
Scienture Holdings Inc trading halted, news pending
TipRanks · 4d ago
Scienture’s Arbli added to formularies at 3 U.S. pediatric academic med centers
TipRanks · 4d ago
EXCLUSIVE: Scienture Expands Institutional Reach for Hypertension Drug with New Hospital Adoptions
Benzinga · 4d ago
SCIENTURE Announces Arbli™ Added to Formularies at Three Leading U.S. Pediatric Academic Medical Centers and Hospitals
Barchart · 4d ago
Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Benzinga · 5d ago
More
About SCNX
Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.

Webull offers Scienture Holdings Inc stock information, including NASDAQ: SCNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCNX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SCNX stock methods without spending real money on the virtual paper trading platform.